These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 7914185)
1. High-dose methylprednisolone treatment-induced changes in immunological parameters in progressive MS patients. Dufour A; Salmaggi A; La Mantia L; Eoli M; Nespolo A; Milanese C Int J Neurosci; 1994 Mar; 75(1-2):119-28. PubMed ID: 7914185 [TBL] [Abstract][Full Text] [Related]
2. T-cell subsets in the cerebrospinal fluid and peripheral blood of multiple sclerosis patients treated with high-dose intravenous methylprednisolone. Frequin ST; Lamers KJ; Borm GF; Barkhof F; Jongen PJ; Hommes OR Acta Neurol Scand; 1993 Aug; 88(2):80-6. PubMed ID: 8213063 [TBL] [Abstract][Full Text] [Related]
3. Double-blind trial of dexamethasone versus methylprednisolone in multiple sclerosis acute relapses. La Mantia L; Eoli M; Milanese C; Salmaggi A; Dufour A; Torri V Eur Neurol; 1994; 34(4):199-203. PubMed ID: 7915989 [TBL] [Abstract][Full Text] [Related]
4. Soluble CD8 and ICAM-1 in serum and CSF of MS patients treated with 6-methylprednisolone. Franciotta D; Piccolo G; Zardini E; Bergamaschi R; Cosi V Acta Neurol Scand; 1997 May; 95(5):275-9. PubMed ID: 9188901 [TBL] [Abstract][Full Text] [Related]
5. Reduced adhesion of PBMNCs to endothelium in methylprednisolone-treated MS patients: preliminary results. Gelati M; Corsini E; Dufour A; Ciusani E; Massa G; Frigerio S; Milanese C; Nespolo A; Salmaggi A Acta Neurol Scand; 1997 Nov; 96(5):283-92. PubMed ID: 9404997 [TBL] [Abstract][Full Text] [Related]
7. Immune parameters associated with early treatment effects of high-dose intravenous methylprednisolone in multiple sclerosis. Wang HY; Matsui M; Araya S; Onai N; Matsushima K; Saida T J Neurol Sci; 2003 Dec; 216(1):61-6. PubMed ID: 14607304 [TBL] [Abstract][Full Text] [Related]
8. Immunological effects of oral high-dose methylprednisolone in acute optic neuritis and multiple sclerosis. Sellebjerg F; Christiansen M; Jensen J; Frederiksen JL Eur J Neurol; 2000 May; 7(3):281-9. PubMed ID: 10886311 [TBL] [Abstract][Full Text] [Related]
9. High interindividual variability in the CD4/CD8 T cell ratio and natalizumab concentration levels in the cerebrospinal fluid of patients with multiple sclerosis. Harrer A; Pilz G; Wipfler P; Oppermann K; Sellner J; Hitzl W; Haschke-Becher E; Afazel S; Rispens T; van der Kleij D; Trinka E; Kraus J Clin Exp Immunol; 2015 Jun; 180(3):383-92. PubMed ID: 25603898 [TBL] [Abstract][Full Text] [Related]
10. CD4+ lymphocyte subsets in the cerebrospinal fluid of multiple sclerosis and non-inflammatory neurological diseases. Zaffaroni M; Gallo L; Ghezzi A; Cazzullo CL J Neurol; 1991 Jul; 238(4):209-11. PubMed ID: 1680167 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of the progression of multiple sclerosis by linomide is associated with upregulation of CD4+/CD45RA+ cells and downregulation of CD4+/CD45RO+ cells. Lehmann D; Karussis D; Mizrachi-Koll R; Linde AS; Abramsky O Clin Immunol Immunopathol; 1997 Nov; 85(2):202-9. PubMed ID: 9344704 [TBL] [Abstract][Full Text] [Related]
12. CD4 and CD8 lymphocyte subsets in cerebrospinal fluid and peripheral blood from patients with multiple sclerosis, meningitis and normal controls. Vrethem M; Dahle C; Ekerfelt C; Forsberg P; Danielsson O; Ernerudh J Acta Neurol Scand; 1998 Apr; 97(4):215-20. PubMed ID: 9576634 [TBL] [Abstract][Full Text] [Related]
13. Treatment with methylprednisolone in relapses of multiple sclerosis patients: immunological evidence of immediate and short-term but not long-lasting effects. Martínez-Cáceres EM; Barrau MA; Brieva L; Espejo C; Barberà N; Montalban X Clin Exp Immunol; 2002 Jan; 127(1):165-71. PubMed ID: 11882048 [TBL] [Abstract][Full Text] [Related]
14. Transient immunomodulation by intravenous methylprednisolone treatment of multiple sclerosis. Crockard AD; Treacy MT; Droogan AG; McNeill TA; Hawkins SA Mult Scler; 1995 Apr; 1(1):20-4. PubMed ID: 9345465 [TBL] [Abstract][Full Text] [Related]
15. Natural killer cells and lymphocyte subsets in active MS and acute inflammation of the CNS. Merelli E; Sola P; Faglioni P; Giordani S; Mussini D; Montagnani G Acta Neurol Scand; 1991 Aug; 84(2):127-31. PubMed ID: 1835239 [TBL] [Abstract][Full Text] [Related]
16. CSF myelin basic protein, IgG and IgM levels in 101 MS patients before and after treatment with high-dose intravenous methylprednisolone. Frequin ST; Barkhof F; Lamers KJ; Hommes OR; Borm GF Acta Neurol Scand; 1992 Sep; 86(3):291-7. PubMed ID: 1384263 [TBL] [Abstract][Full Text] [Related]
17. Soluble and cell surface ICAM-3 in blood and cerebrospinal fluid of patients with multiple sclerosis: influence of methylprednisolone treatment and relevance as markers for disease activity. Kraus J; Oschmann P; Engelhardt B; Bauer R; Schiel C; Kern A; Stolz E; Traupe A; Dorndorf W Acta Neurol Scand; 2000 Feb; 101(2):135-9. PubMed ID: 10685862 [TBL] [Abstract][Full Text] [Related]